INO Stock Gets Increased EPS Forecast from HC Wainwright

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) – Equities research analysts at HC Wainwright increased their Q1 2027 EPS estimates for shares of Inovio Pharmaceuticals in a research report issued to clients and investors on Monday, November 2nd. HC Wainwright analyst R. Selvaraju now expects that the biopharmaceutical company will post earnings of ($0.12) per share for the quarter, up from their previous estimate of ($0.15). HC Wainwright has a “Buy” rating and a $5.00 price target on the stock. The consensus estimate for Inovio Pharmaceuticals’ current full-year earnings is ($0.72) per share. HC Wainwright also issued estimates for Inovio Pharmaceuticals’ Q2 2027 earnings at ($0.06) EPS, Q3 2027 earnings at $0.02 EPS, Q4 2027 earnings at $0.12 EPS and FY2027 earnings at ($0.03) EPS.

Inovio Pharmaceuticals (NASDAQ:INO) last released its quarterly earnings results on Wednesday, August 12th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.15.

INO has been the topic of several other research reports. Weiss Ratings downgraded shares of Inovio Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, August 13th. Jefferies Financial Group upgraded shares of Inovio Pharmaceuticals from a “hold” rating to a “positive” rating and raised their target price for the stock from $1.80 to $3.00 in a research report on Thursday, August 13th. Zacks Research cut shares of Inovio Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 12th. Piper Sandler reiterated an “overweight” rating and issued a $4.00 price target on shares of Inovio Pharmaceuticals in a report on Monday, August 3rd. Finally, Wall Street Zen raised Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $4.00.

Inovio Pharmaceuticals Trading Down 12.2%

Shares of NASDAQ INO opened at $1.66 on Wednesday. Inovio Pharmaceuticals has a 12 month low of $0.56 and a 12 month high of $2.72. The company has a 50-day simple moving average of $1.16 and a 200-day simple moving average of $1.27.

Institutional Trading of Inovio Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Eversept Partners LP purchased a new stake in Inovio Pharmaceuticals in the 1st quarter valued at about $1,802,000. Renaissance Technologies LLC lifted its holdings in shares of Inovio Pharmaceuticals by 16.4% during the 1st quarter. Renaissance Technologies LLC now owns 643,777 shares of the biopharmaceutical company’s stock worth $1,120,000 after acquiring an additional 90,613 shares during the period. Green Alpha Advisors LLC lifted its holdings in shares of Inovio Pharmaceuticals by 68.8% during the 3rd quarter. Green Alpha Advisors LLC now owns 114,857 shares of the biopharmaceutical company’s stock worth $140,000 after acquiring an additional 46,802 shares during the period. LexAurum Advisors LLC purchased a new position in shares of Inovio Pharmaceuticals during the 3rd quarter worth about $118,000. Finally, Prime Capital Investment Advisors LLC lifted its holdings in shares of Inovio Pharmaceuticals by 312.4% during the 3rd quarter. Prime Capital Investment Advisors LLC now owns 70,636 shares of the biopharmaceutical company’s stock worth $86,000 after acquiring an additional 53,510 shares during the period. Hedge funds and other institutional investors own 26.79% of the company’s stock.

More Inovio Pharmaceuticals News

Here are the key news stories impacting Inovio Pharmaceuticals this week:

• Positive Sentiment: The FDA granted accelerated approval to VOCERYQ, Inovio’s first commercial product, to reduce surgery frequency in adults with recurrent respiratory papillomatosis (RRP). The company says it is the first FDA-approved DNA medicine, providing a major regulatory and commercial milestone. Inovio’s DNA-Based Immunotherapy Lands Speedy FDA Nod for Rare Type of Tumor
• Positive Sentiment: HC Wainwright upgraded INO from Neutral to Buy and raised its 2027 earnings outlook. Its FY2027 EPS forecast improved to a loss of $0.03 from a loss of $0.21, and it projects positive EPS in Q3 and Q4; its price target is $5.00. The improved estimates may support sentiment, though they remain one analyst’s projections. HC Wainwright & Co. upgrades Inovio Pharmaceuticals to buy from neutral
• Neutral Sentiment: Inovio plans to report third-quarter results on November 10, which could provide investors with an update on finances and business plans. INOVIO to Report Third Quarter 2026 Financial Results on November 10, 2026
• Negative Sentiment: The shares had surged sharply after the FDA announcement, leaving room for profit-taking and heightened volatility. Recent coverage also flags potential caveats around VOCERYQ’s data and the launch outlook, which may temper enthusiasm as investors assess its commercial prospects. Inovio’s VOCERYQ Data Cut Both Ways as Launch Clock Starts Ticking

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc is a biotechnology company focused on developing DNA medicines, including DNA-based vaccines and immunotherapies designed to treat or prevent infectious diseases, cancers and other serious conditions. The company’s platform is intended to stimulate targeted immune responses by delivering DNA medicines into cells.

Inovio’s product pipeline has included investigational therapies such as INO-3107, a DNA immunotherapy being developed for recurrent respiratory papillomatosis, and other candidates targeting cancer and infectious diseases.